8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Is it possible to eliminate hepatitis C from the prisons of Catalonia, Spain, in 2021? Translated title: ¿Es posible eliminar la hepatitis C en las prisiones de Cataluña en el 2021?

      research-article
      1 , 2 , 1 , 1 , 3 , 4 , 5 , 2 , 6 , GRUMIP* (GRUMIP or Grup de Control de Malalties Infeccioses en el Àmbit Penitenciari)
      Revista Española de Sanidad Penitenciaria
      Sociedad Española de Sanidad Penitenciaria
      hepatitis C, disease eradication, prisons, time series studies, epidemiology, hepatitis C, erradicación de la enfermedad, prisiones, estudios de series temporales, epidemiología

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Aim:

          Predict the elimination of chronic hepatitis C in Catalan prisons.

          Material and method:

          We analyzed the trend of the prevalence of HCV-RNA and anti-hepatitis C treatments prescribed in Catalonia in the period 2002-2016. Using linear exponential smoothing from the historical values in the time series, we estimate the time required to eliminate hepatitis C as a public health problem in prisons (prevalence of hepatitis C virus RNA<1%).

          Results:

          A total of 1264 treatments were administered by 12/31/2016. The prevalence of hepatitis C virus RNA was 31.2% in 2002, decreasing to 8.81% in 2016. We estimate that prevalence will reach 0-0.5% in 5 years (second half 2021; 95% CI: 2019-2025).

          Discussion:

          Appropriate actions can eliminate hepatitis C infection in prisoners. We estimate that by 2021 hepatitis C infection will no longer be a public health problem in Catalonia prisons.

          RESUMEN

          Objetivo:

          Predecir la eliminación de la hepatitis C crónica en las prisiones de Cataluña.

          Material y método:

          Se analiza la tendencia de la prevalencia de ácido ribonucleico (ARN)-virus de la hepatitis C (VHC) y los tratamientos antihepatitis C prescritos en Cataluña en el periodo 2002-2016. Mediante un alisado exponencial de los valores históricos de la serie, se calcula el tiempo en que podrá eliminarse la hepatitis C en Cataluña como problema de salud pública (prevalencia ARN-VHC<1%).

          Resultados:

          Hasta el 31 de diciembre de 2016, se habían prescrito 1.264 tratamientos. La prevalencia de ARN-VHC fue del 31,2% en 2002, y drecreció hasta el 8,8% en 2016. Se estima que la prevalencia alcanzará una tasa del 0-0,5% en cinco años (segundo semestre de 2021; intervalo de confianza, IC, del 95%: 2019-2025).

          Discusión:

          Con las acciones adecuadas, puede y debe eliminarse la hepatitis C en los presos. En Cataluña, esta enfermedad dejaría de ser un problema de salud pública en 2021.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates.

          Chronic hepatitis C treatment with direct acting antiviral (DAA) therapy during incarceration is an attractive option, due to its short duration and to the possibility of directly observed treatment or supervision. The aim of this study is to compare the effectiveness and rates of discontinuation of DAA treatment in prisoners and nonprisoners. We studied all patients treated in the 10 prisons of Catalonia and at 3 public hospitals in the Barcelona area between 1 January 2015 and 30 April 2016. We analysed sustained viral response (SVR) and rates of discontinuation through intention-to-treat and modified-intention-to-treat analyses, the latter excluding discontinuations due to release from prison. One hundred and eighty-eight inmates and 862 noninmates were included. Prisoners were significantly younger than nonprisoners, with higher proportions of men, drug users, HIV infection, genotypes 1a and 3 and more treatment with psychiatric drugs. Overall, 98.4% of patients completed treatment. The discontinuation rate was low, but higher in inmates (3.7% vs 1.2% noninmates; P = .003) and in community patients >65 years old (2.8% vs 1.2% in under 65 seconds; P = .008). Among the inmates, 7 (42.8%) discontinuations were due to release. SVR was 93.1% in inmates vs 96.5% in noninmates (P = .08) by intention-to-treat and 95.1% vs 96.5% (P = .37) by modified intention-to-treat. Virologic failure rates were similar (3.8% vs 3% in noninmates; P = .60). SVR, virologic failure and discontinuation rates were similar in inmates and noninmates. Currently, prisons are considered a priority for the implementation of DAA. Improved coordination between penitentiary and community health systems would help to ensure therapeutic continuity in released prisoners.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Is elimination of hepatitis C from the UK by 2030 a realistic goal?

              Highly effective, combination therapy for chronic hepatitis C virus (HCV) infection is now available. Current cure rates are close to 100% and applicable to all patients irrespective of race, age, severity of liver disease or viral genotype. Remarkably for persistent infection, current treatment is recommended for as little as 12 weeks; recent studies suggest even shorter courses. In contrast to interferon-based therapy, present regimens have few side effects and serious adverse events are rare. The success and safety of these regimens has stimulated interest in the possible eventual elimination of HCV. Barriers to elimination include cost of drugs and finding patients in the community less likely to interact with medical services who are a potential reservoir of infection.
                Bookmark

                Author and article information

                Journal
                Rev Esp Sanid Penit
                Rev Esp Sanid Penit
                sanipe
                Revista Española de Sanidad Penitenciaria
                Sociedad Española de Sanidad Penitenciaria
                1575-0620
                2013-6463
                Jan-Apr 2019
                01 June 2019
                : 21
                : 1
                : 38-41
                Affiliations
                [1 ] originalPrison Health Programme. Catalonian Health Institute orgdiv1Prison Health Programme orgnameCatalonian Health Institute Spain
                [2 ] originalCentre for Biomedical Research on the Epidemiology and Public Health Network (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)) orgnameCentre for Biomedical Research on the Epidemiology and Public Health Network Spain
                [3 ] originalPrimary Prison Healthcare Team of Roca del Vallés-1, Barcelona orgnamePrimary Prison Healthcare Team of Roca del Vallés-1 Barcelona, Spain
                [4 ] originalPrimary Prison Healthcare Team of Sant Esteve Sesrovires-1, Barcelona orgnamePrimary Prison Healthcare Team of Sant Esteve Sesrovires-1 Barcelona, Spain
                [5 ] originalPrimary Prison Healthcare Team of Sant Esteve Sesrovires-2, Barcelona orgnamePrimary Prison Healthcare Team of Sant Esteve Sesrovires-2 Barcelona, Spain
                [6 ] originalEpidemiology Service. Public Health Agency of Barcelona orgdiv1Epidemiology Service orgnamePublic Health Agency of Barcelona Spain
                Author notes
                CORRESPONDENCE;: Andrés Marco. Enfermedades Infecciosas. Programa de Salud Penitenciaria Gran Vía de les Corts Catalanes, 587-589. Barcelona, 08007. E-Mail: amarco@ 123456gencat.cat andres.marco.m@ 123456gmail.com
                Article
                00006
                6788204
                31498858
                028c3167-bbd6-477b-88b6-8ca6474719ec

                This is an open-access article distributed under the terms of the Creative Commons Attribution License

                History
                : 29 January 2018
                : 17 July 2018
                Page count
                Figures: 1, Tables: 0, Equations: 0, References: 8, Pages: 04
                Categories
                Short Original

                hepatitis c,disease eradication,prisons,time series studies,epidemiology,erradicación de la enfermedad,prisiones,estudios de series temporales,epidemiología

                Comments

                Comment on this article